Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA
Authors
Keywords
-
Journal
Applied Health Economics and Health Policy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-01
DOI
10.1007/s40258-023-00844-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas
- (2022) Paul A. Christensen et al. AMERICAN JOURNAL OF PATHOLOGY
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
- (2022) Don Husereau et al. VALUE IN HEALTH
- Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
- (2022) Rui Li et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England
- (2022) Freja C M Kirsebom et al. LANCET INFECTIOUS DISEASES
- Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years
- (2022) Ronen Arbel et al. NATURE MEDICINE
- Waning of SARS-CoV-2 booster viral-load reduction effectiveness
- (2022) Matan Levine-Tiefenbrun et al. Nature Communications
- Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
- (2022) Hiam Chemaitelly et al. Nature Communications
- Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study
- (2022) Sarah M Bartsch et al. Lancet Public Health
- Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
- (2022) Tal Patalon et al. Nature Communications
- Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
- (2022) Ruth Link-Gelles et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
- (2021) Moriah Bergwerk et al. NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021
- (2021) et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
- (2021) Salim S Abdool Karim et al. LANCET
- Booster shots for COVID-19—the debate continues
- (2021) Talha Burki LANCET INFECTIOUS DISEASES
- A strategic approach to COVID-19 vaccine R&D
- (2020) Lawrence Corey et al. SCIENCE
- Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study
- (2020) Krishna P Reddy et al. Lancet Global Health
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modelling the Epidemiology of Infectious Diseases for Decision Analysis
- (2011) Mark Jit et al. PHARMACOECONOMICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started